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A B S T R A C T
Objective: This study attempts to identify a structure among patient-related factors that could predict
treatment adherence in statin patients, especially with regards to the necessity-concern framework.
Methods: 414 Swedish patients using statins completed a questionnaire about their health, treatment,
locus of control, perception of necessity-concern and adherence. The data were handled using a
structural equation modeling approach.
Results: Patients that reported high perceptions of necessity to treatment seemed to adhere well, and
side effects appear to affect adherence negatively. Disease burden, cardiovascular disease experience and
high locus of control seem to have mediating effects on adherence.
Conclusion: This study provides support for the hypothesis that health- and treatment-related factors, as
well as locus of control factors, are indirectly associated with treatment adherence via their association
with mediating factor necessity.
Practice implications: This study highlights the importance of considering patients’ beliefs about
medications, disease burden, experience of cardiovascular events and locus of control as these factors are
associated with adherence behavior to statin treatment. This study also emphasizes more generally the
importance of an approach targeting necessity and concern when communicating with and treating
patients with lipid-lowering medication.
 2012 Elsevier Ireland Ltd. 
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Cardiovascular disease (CVD) is the leading cause of death in the
industrialized world [1,2]. Dyslipidemia is an important risk factor
for CVD, estimated to cause 18% of cerebrovascular disease and 56%
of ischemic heart disease [3]. Cholesterol lowering has been the
primary goal of therapies aimed at CVD risk reduction, and several
randomized studies have demonstrated the beneﬁts of statins
(hydroxymethylglutaryl-CoA reductase inhibitors) in the reduc-
tion of cardiovascular-related events within high-risk patient
groups [4]. Currently, statin drug treatment is one of the most
important treatment strategies when managing patients with, or
at high risk of, CVD.
Adherence is deﬁned as the extent to which a person’s behavior,
such as taking medication, following a diet or executing lifestyle* Corresponding author at: Department of Public Health and Caring Sciences,
Uppsala University, Box 564, SE-751 22 Uppsala, Sweden. Tel.: +46 18 471 6553;
fax: +46 18 471 6675.
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Open access under CC BY-NC-ND license.changes, corresponds with the recommendations from a health
care provider [5]. Poor adherence has been shown to be an
important factor for treatment failure when looking at both high
cholesterol levels [6] and morbidity [7–9], and, as a result, non-
adherence to treatment is considered to be a cardiovascular risk
factor [10]. Adherence to long-term pharmacological therapy for
chronic illnesses in developed countries averages 50% [5], and for
lipid-lowering pharmacological therapies the long-term adher-
ence is poor and declining considerably over time.
In 2003, the World Health Organization (WHO) described
adherence as a phenomenon determined by ﬁve dimensions:
patient-related factors, social and economic factors, health care
team and system-related factors, condition-related factors and
therapy-related factors [5]. To describe adherence and for the
analysis of non-adherence among patients with CVD, hypertension
and other long-term therapies, a large number of hypotheses and
factors have been proposed [11].
Several models that aim to explain health behavior are based on
patients weighing positive and negative perceptions for a
treatment or health advice, where the balance directs the behavior.
The models that been used in adherence studies are the Health
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Protection Motivation Theory [15,16] and the Self-Regulatory
Model (SRM) [17,18]. The SRM proposes that health-related
behaviors are cognitive responses inﬂuenced by a patient’s
perception of treatment and emotional response to treatment.
These responses can be derived from both manifest symptoms and
concern about a health threat, or experience or concern about side
effects from a treatment.
Inﬂuenced by the earlier models, the necessity-concern
framework (NCF) was developed to speciﬁcally investigate drug
treatment adherence [19]. According to the NCF, a patient’s
decision regarding adherence is the result of a trade-off between
the patient’s perceived need for a prescribed treatment (necessity)
and their worries about the potential adverse effects as a result
(concern). In this study, we chose to assess patients’ beliefs using
the NCF as it has been used in a broad range of different
quantitative studies exploring drug treatment adherence [20–23],
especially for cardiovascular diseases [24–27].
Some factors seem to be more related than others. Factors with
a high probability of affecting adherence include gender [28],
demographics [29,30], patient understanding and perception of
medication [5], sickness- and treatment-related factors [31–34],
and health locus of control [35]. The health locus of control model
is deﬁned by three different dimensions: an individual’s sense of
control over their health is directly related to their own beliefs and
actions (internal); to chance externality (chance); or to the
inﬂuence of other important persons (powerful others) [36]. There
is support for the idea that a person’s locus of control is associated
with health behavior, mainly in combination with other predictive
factors [37]. Qualitative studies suggest that individuals with a
strong locus in powerful others might be more adherent to the
recommendations of health care professionals [38].
To date, how these (and other) factors are related to adherence
and non-adherence for patients with CVD has not been fully
explored, and there is little information available regarding how
strong the inﬂuence of these factors is on adherence in adjusted
models. This study attempts to identify a structure among factors
regarding demographic, health and treatment factors, locus of
control, NCF and adherence in patients using statins. The aim is to
present a model that describes the relationships between the
central variables and a measurement structure that possibly
predicts adherence within patient groups at high risk of CVD.
2. Methods
For this study, a cross-sectional study design was applied. A
total of 600 postal questionnaires were distributed in May 2009 to
the 28 operating pharmacies within the county of Uppsala in
central Sweden. The number of questionnaires distributed to each
pharmacy was proportional to the number of previous statin
prescription sales. The employees of each pharmacy were
instructed to invite every patient who visited the pharmacy for
the preparation of their statin prescription. There were no
inclusion criteria other than the statin prescription requisite,
and no exclusion criteria. Patients agreeing to participate, after
receiving oral and written information about the study by the
pharmacist, were handed a questionnaire to take home and
complete, and then return by post. The number of patients
declining to participate was registered for control of non-
participants. The ﬁrst page of the questionnaire contained precise
information on the purpose of the study. Completed question-
naires were returned anonymously in a prepaid envelope. All
questionnaires returned within three months were included in the
study. A total of 697 statin users were asked to participate: 109
declined to participate and 588 questionnaires were handed
out (one pharmacy failed to distribute their questionnaires).Questionnaires were returned by 414 individuals, making the
response rate of the distributed questionnaires 70.4% (414/588)
and the overall response rate 59.4% (414/697).
2.1. Measures in questionnaires
The questionnaire contained a total of 76 questions. The main
data types and measures that were included were:
Demographic data: This was collected using questions that
assessed the respondent’s gender, age, occupation and educational
level, including compulsory school, secondary school (or equiva-
lent) and university.
Health-, disease- and treatment-related factors: Data were
collected using a list of 14 common health problems (used as a
cumulative measure of disease burden and number of health
problems), cardiovascular disease experience (myocardial infarc-
tion and/or angina), perceived satisfaction with treatment
explanations made by a physician, and time on statin treatment;
these questions have been used earlier [39]. Experiences or worries
of side effects and difﬁculties swallowing solid doses can affect
adherence negatively [34], and data were assessed by the question:
Do you experience any of this unpleasantness when taking your
statins? (a) Yes, I feel that I have trouble swallowing tablets, (b)
Yes, I feel that I encounter unpleasant side effects from them, (c)
No, I do not feel any unpleasant reactions related to my treatment.
The variable was scored as a count variable.
Health locus of control: These data were measured using the
Multidimensional Health Locus of Control (MHLC) 18-item test
[36]. MHLC is a measurement instrument that includes three six-
point Likert scales: Internal (MHLC-I), Chance externality (MHLC-
C) and Powerful others (MHLC-PO). The different scales, or levels,
were analyzed separately. In this study, the MHLC scales were
treated as index only in the correlation matrix.
Beliefs about medicines: Results were measured using NCF based
on the Beliefs about Medicines Questionnaire-Speciﬁc (BMQ-S)
[19]. BMQ-S is a validated 10-item test instrument which assesses
beliefs about perceived medication necessity and perceived
medication concerns on ﬁve-point Likert scales. BMQ is a two-
scale construction and is also available to use as an index. In this
study, the index was only used in the correlation matrix. The BMQ
questionnaire has been translated into Swedish, with a back
translation approved by the original author of the questionnaire,
and has been previously used in Sweden [40–43].
Medication adherence: These data were self-reported using the
Morisky scale of adherence (MSA) in a four-item form [44]. The
MSA is a count variable and the ﬁrst question is: ‘‘Do you ever
forget to take your medicine?’’. The Morisky scale was originally
designed to evaluate medication adherence in hypertensive
patients, but has subsequently been found to be reliable in a
variety of adherence studies [45,46]. In previous statin studies, the
MSA used was binary, with only two categories [47]. Patients who
answered ‘‘no’’ to all questions were categorized as highly
adherent, while patients who answered ‘‘yes’’ to at least one
question were categorized as having low adherence. This
categorization system is consistent with what was used when
developing the original scale, as well as how it has been used in
several adherence studies [47,48].
2.2. Method of data analysis
The Statistical Package for the Social Sciences version 19
(Chicago, IL, USA) was used for descriptive statistics, factor
analysis, to measure the variance inﬂation factor (VIF), and Chi-
square and Mann–Whitney U tests. WarpPLS vs. 2.0 was used for
structural equation modeling (SEM) analysis with the partial least
squares (PLS) estimation technique [49]. SEM is a combination of
Necess ity-Concern
Fram ework
Internality 
Chance 
Power ful others
NECES SITY
CONCERN
Mul dimensional He alt h 
Locus of Control
Dem ographic
Gender
Age
Educaon
Occup aon
Health- and  treatment-
rela ted factors
Diseas e bu rden
CVD ex perie nce
Expla naon 
sasfac on
Treatment me 
Side eﬀec ts
Behavi or rela ted to 
Medicaon
ADHERENCE
Backg round  variables Mediang va riables Depend ent variable
Fig. 1. Research framework.
This BATLoC model outlines the theoretical direct and indirect relationships between the background variables: demographics, health- and treatment-related factors, MHLC
and the mediating variables in NCF and the dependent variable adherence.
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of latent variables (LV) that are not directly measured [50]. SEM
works with both continuous and discrete observed variables as
indicators (LVs). SEM is a second-generation statistical method
that, in contrast to regression, allows for the simultaneous
assessment of multiple independent and dependent constructs,
including multi-step paths [51] and mediating effects [52]. LVs
differ from the observed sum scores (index) of the indicators as
they can account for measurement errors in the items, and items
are allowed differential weights in estimating the latent construct
[53]. In essence, LVs can be formative or reﬂective. The difference isTable 1
Characteristics of the study group (n = 414).
Sex Male (%) 
Female (%) 
Age, mean (s.d.) 
Education Compulsory school (%) 
Secondary school (%) 
University (%) 
Occupation Full- or part-time work (%) 
Not in workforce (%) 
Disease burden Low (%) 
Medium (2–4) (%) 
High (%) 
Cardiovascular disease No experience (%) 
Experience (%) 
Satisfaction with treatment explanation None or poor (%) 
Fair (%) 
Good or very good (%) 
Treatment time Less than 2 years (%) 
Between 2 and 5 years (%) 
More than 5 years (%) 
Side effects No (%) 
Yes (%) 
MHLC, indexform Internal (MD) 
Chance (MD) 
Powerful others (MD) 
BMQ, indexform Necessity (MD) 
Concerns (MD) 
a Chi-squared test.
b Mann–Whitney U test.in the direction of theoretical causality between measures and
constructs. Reﬂective measures are theoretically caused by the
latent construct, whereas formative measures theoretically cause
the latent construct [54].
SEM was conducted using the PLS estimation technique with
Wold’s algorithm [55–57]. PLS is a modeling approach with a
ﬂexible technique, which can handle data with missing values,
strongly correlated variables and small samples. SEM-PLS is a well-
suited method for exploratory research and theory development
[58], which was the purpose of this study. SEM-PLS has also been
used for adherence studies [59,60]. SEM works with two models:High adherent Low adherent Total P
27.6 23.2 50.8 0.898a
27.0 22.2 49.2
64.6 (10.0) 63.3 (9.1) 64.2 (9.5) 0.197b
21.9 18.0 39.9 0.636a
16.7 12.3 29.1
16.0 15.0 31.0
21.5 19.6 58.9 0.391a
33.4 25.5 41.1
15.9 17.0 32.9 0.234a
27.3 19.7 47.1
11.1 8.9 20.0
37.9 34.6 72.6 0.184a
16.4 11.0 27.4
4.2 4.4 8.6 0.506a
9.8 9.6 19.4
40.5 31.4 72.0
20.4 17.9 38.3 0.850a
14.7 12.5 27.3
19.4 15.0 34.4
50.4 37.7 88.0 0.021a
4.7 7.2 12.0
23 23 23 0.513b
17 16 17 0.820b
20 19 19 0.050b
17 15 17 0.000b
11 11 16 0.133b
Table 2
Correlation analysis among indicators (observed variables).
Min Max Std.dev. 1 2 3 4 5 6 7 8 9 10 11 12 13 14
1. Gender 1 2 .50
2. Age 22 89 9.52 .06
3. Education level 1 3 .84 .09 .27**
4. Occupation 0 1 .49 0 .73** .25**
5. Disease burden 1 3 .72 .05 .06 .02 .13*
6. CVD experience 0 1 .45 .16** .18** .12* .11* .18**
7. Treatment explanation satisfaction 1 5 .97 .06 .04 .13** .09 .04 .01
8. Treatment time 1 3 .85 .09 .24** .08 .22** .19** .24** .01
9. Sideeffects 0 1 .32 .02 .06 .11* .10* 0.02 .02 .02 .00
10. MHLC Internal 6 36 5.37 .17** .05 .02 .03 .13* .10* .09 .06 .04
11. MHLC Chance 6 33 4.59 .03 .12* .27** .15** .12* .01 .06 .11* .02 .18**
12. MHLC Powerful other 7 36 5.26 .22** .24** .11* .17** .02 0.10 .14** .11* .02 .22** .21**
13. Necessity 5 25 3.82 .01 .11* .13** .12* .26** .20** .07 .25** .00 .02 .10* .27**
14. Concern 5 23 4.30 0 .09 .04 .08 0.08 .07 .20** .01 .18** .02 .10* .08 .23**
15. Adherence 0 1 .50 .01 .06 .02 .04 0.05 .07 .07 .02 .12* .03 .01 .10 .22** .08
Max. min. standard deviations and correlations indicators. This matrix has been calculated with Spearman’s signiﬁcant test. Indices were used for multidimensional health
locus of control, perception of necessity and concern and adherence. All indicators in the model were coded so that (hypnotized) higher scores on the independent variable
also indicate higher scores on the outcome variable, if there was a positive association.
* Correlation is signiﬁcant at the 0.05 level.
** Correlation is signiﬁcant at the 0.01 level.
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determines the relationships between observed manifesting
variables and their association with latent variables; and (II) a
structural model (also called the ‘‘inner model’’), relating latent
variables to other latent variables. PLS estimates loading and path
parameters between latent variables and maximizes the variance
explained for the dependent variables. The WarpPLS program can
handle linear as well as S- and U-shaped relationships between
variables. The paths in the model were tested for signiﬁcance using
the bootstrapping procedure, with 200 cases of resamplingFig. 2. SEM analysis of data outlined after the framework.
(*) Patch is signiﬁcant at the 0.05 level.
(**) Patch is signiﬁcant at the 0.01 level.
(***) Patch is signiﬁcant at the 0.001 level.
SEM analysis generated through a partial least squares estimation technique, with path co
hypnotized relationships among the latent variables in the BATLoC model. To test whet
health- and disease-related factors were tested directly against adherence in the modeincorporated in WarpPLS. Signiﬁcant mediating effects were
calculated using the Sobel test [61].
Model ﬁt indicators are important in SEM since they offer
comparable measurements. Model ﬁt indicators apply to the degree
of correspondence between the observed data and the model-
implied data. The degree of correspondence is determined by a
function of the sum of the squared deviations between the observed
sample covariance matrix and the model-implied covariance matrix.
In WarpPLS, the output model ﬁt is assessed by three indices:
average path coefﬁcient (APC), average R-squared (ARS) andefﬁcients of the structural pathway model (i.e. inner model). The model outlines the
her direct effects had an impact on adherence, the demographic factors, MHLC and
l. Signiﬁcant associations between latent variables are presented in bold.
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WarpPLS includes APC and ARS is to enable an acceptable
comparison between different models, which is why these measures
are of lower importance in studies like this, where each path is
independently important. However, ﬁgures for APC and ARS should
both be under 2 and should both be statistically signiﬁcant
(p < 0.05), while the value for AVIF is recommended to be below 5.
2.3. Research framework and model construction
A research model of balanced adherence inﬂuenced by
treatment and locus of control factors (BATLoC) was constructed
to examine the relationships between the variables (Fig. 1). The
model contains one dependent (adherence), two mediating
(perception of necessity and perception of concern), and twelve
independent LVs. The twelve background LVs were divided into
three groups: demographic variables (gender, age, education level
and occupation); health- and treatment-related variables (disease
burden, cardiovascular disease experience, treatment explanation
satisfaction, treatment time and side effects); and health locus of
control variables (on three levels: internal, chance and powerful
others).
3. Results
The average age of the study population was 64.2 years
(S.D.  9.5), and the group consisted of slightly more men (51.1%)
than women (48.9%). Compulsory school was the most commonly
completed education level (40.0%). Approximately 40.6% of the group
were in full-time or part-time work, while the remaining 59.4% were
unemployed or retired from the work market. The distribution of
demographics and key variables in the study population is shown in
Table 1.
3.1. Adherence and cardiovascular diseases
In the whole group, 54.5% of patients were classiﬁed to have
high adherence, and 45.5% were classiﬁed to have low adherence to
their statin treatment. About one-ﬁfth of the group reported a high
disease burden (suffering from ﬁve or more diseases) and half of
the group had between two and four diseases. Overall, 72.8% of the
patients did not report any CVD experience, and therefore received
their treatment as primary prevention, 27.2% of the group reported
at least one CVD experience, so received their treatment as
secondary prevention. The majority of the group did not report any
side effects, but 11.9% did experience some side effects.Table 3
Path coefﬁcients and P-values of direct effects on NCF and adherence.
Background variables Mediating variables 
Necessity Co
Path coefﬁcients P-Value Pa
Gender 0.04 0.199 0
Age 0.02 0.188 0
Education level 0.10 0.033 0
Occupation 0.03 0.486 0
Disease burden 0.20 <0.001 0
CVD experience 0.17 <0.001 0
Explanation satisfaction 0.13 0.008 0
Treatment time 0.14 <0.001 0
Side effects 0.04 0.102 0
MHLC internal 0.00 0.363 0
MHLC chance 0.02 0.416 0
MHLC powerful other 0.33 <0.001 0
Necessity 
Concern 3.2. Multidimensional health locus of control and beliefs about
medicines
The Mann–Whitney U test in Table 1 showed no signiﬁcant
difference on internal or chance between patients with low and
high adherence, only small differences were seen on the MHLC
index scales.
3.3. Correlation matrix
Several of the associations outlined in the research framework
(Fig. 1) were also signiﬁcant in the correlation matrix (Table 2). The
highest correlation to the adherence variables was seen with the
perception of necessity of treatment. The indicator variables were
tested for multicollinearity, and no variable had over 2.5 in VIF,
which indicates that the risk for multicollinearity can be
considered to be low. These imply acceptability of using a
structural equation model.
3.4. Full model and PLS-SEM analysis
A PLS estimation procedure was used to examine the
hypothesized relationships (Fig. 2) between constructs depicted
in the theoretical framework (Fig. 1). The SEM analysis showed a
signiﬁcant relationship between adherence and necessity of
treatment (b = 0.15, p = 0.010), but not with concern (Table 3).
The explanatory variables were also tested directly against
adherence, and it was found that side effects (b = 0.14,
p = 0.006) had a signiﬁcant effect on adherence.
The analysis showed that education level (b = 0.10, p = 0.033),
disease burden (b = 0.20, p < 0.001), CVD experience (b = 0.17,
p < 0.001), satisfaction with treatment explanations made by a
physician (b = 0.13, p = 0.008), treatment time (b = 0.14,
p < 0.001) and powerful others in locus of control (b = 0.33,
p < 0.001) each had an effect on perception of the necessity of
treatment. In addition, education level (b = 0.09, p = 0.017),
satisfaction with treatment explanations made by a physician
(b = 0.26, p < 0.001), side effects (b = 0.17, p < 0.001), MHLC-C
(b = 0.09, p = 0.025) and MHLC-PO (b = 0.14, p = 0.001) all had an
effect on concern. In total, these variables could explain almost 31%
of the variance seen in perception of necessity (R2 = 0.31) and 16%
of the variance seen in perception of concern (R2 = 0.16) and 6% of
the variance seen in adherence (R2 = 0.06).
Three background LVs had signiﬁcant mediating effects on
adherence (through necessity of treatment): disease burden
(b = 0.03, p = 0.034), CVD experience (b = 0.03, p = 0.034) and
powerful others (b = 0.05, p = 0.019).Dependent variable
ncern Adherence
th coefﬁcients P-Value Path coefﬁcients P-Value
.06 0.124 0.02 0.310
.06 0.356 0.04 0.269
.09 0.017 0.02 0.358
.01 0.303 0.01 0.407
.06 0.328 0.02 0.378
.06 0.108 0.02 0.242
.26 <0.001 0.06 0.127
.08 0.272 0.05 0.225
.17 <0.001 0.14 0.006
.03 0.325 0.05 0.179
.09 0.025 0.05 0.191
.14 0.001 0.05 0.191
0.15 0.010
0.08 0.067
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The whole model demonstrated an acceptable ﬁt to the data for
APC = 0.081 (p < 0.001), ARS = 0.176 (p < 0.001) and AVIF = 1.269.
4. Discussion and conclusion
This study aimed to create and examine a model that could
contribute to the understanding and predictability of adherence
within patient groups at risk of CVD. A new model and structure
was outlined that tested the associations of demographics, health
and treatment, locus of control on NCF and adherence. Most factors
included were already known to have an impact on adherence. A
primary aim was to create a model that could handle the whole
framework simultaneously.
4.1. Discussion
In this study of statin users, high belief in treatment necessity
has a positive association with adherence, while concerns about
treatment seem to have little association with adherent behavior.
This indicates that patients seem to attach more importance to
factors other than a negative association with drugs when it comes
to actual treatment behaviors.
Among the background variables, disease burden, CVD experi-
ence, treatment time and powerful others in locus of control seem
to have positive relationships with belief in treatment necessity.
Three of the background variables also had a signiﬁcant mediating
effect on adherence through the perception of necessity: disease
burden, CVD experience and locus of control through powerful
others. This means that these factors have a positive impact on
adherence behavior through mediating necessity of treatment.
These ﬁndings are interesting in several ways, especially as factors
that increase sickness severity seem to increase the perceived
necessity of treatment, and therefore contribute to a higher
adherence. This is logical, since a patient at higher risk of a disease
also has more to gain from a risk-lowering treatment. However, in
earlier studies this association did not become evident at a patient
level [39].
Higher education and satisfaction with treatment explanations
made by a physician were negatively associated with concerns that
the patients held about their medications. Side effects and high
belief in chance and powerful others seem to increase the concerns
that the patients reported about their medical treatment. Side
effects and fear of potential side effects are well known to be
important factors for non-adherence [62].
A high satisfaction with the treatment explanation was
associated with a higher perception of necessity of treatment
and lower concerns about treatment. This is consistent with earlier
studies which have shown that the communication of related
issues between patients and physicians has an impact on
adherence [30]. Physicians and health care personnel in general
might also be viewed as powerful others by patients, which is also
measured as a locus of control variable. Powerful others were
positively associated with necessity of and concerns about
treatment, with necessity showing the strongest association.
These results are consistent with the study performed by
Gillibrand and Flynn, who found an association between powerful
others and the ability to cope with long-term treatments [38].
The results show that disease burden had a positive association
with necessity of treatment, and a mediating effect on adherence.
An explanation could be that a person with many diseases has
more contact with health care providers, and is provided with
more information and encouragement in order to manage their
health care problems.The factors in this model explained 6% of adherence in this
study. That may seem low, but it is in the same range that other
studies have shown for patients in this medical group [63]. NCF has
a higher potential, and Horne and Weinman indicated that patient
beliefs about medications contributed to about one-ﬁfth of the
total variance in the adherence behavior of patients with chronic
physical illness [32]. However, this indicates that adherence is
associated with other variables to a large extent. Another type of
adherence measure could possibly have obtained a different result,
but adherence is generally a complex behavior to measure [64].
Four of the factors had more than one signiﬁcant path.
Experiences of side effects appeared to both lower adherence
and increase concern, and this outcome seems logical. Experience
of side effects was also the only background variable that had a
direct impact on adherence, which is a behavior that has been seen
in other patient groups as well [65]. In addition, satisfaction with
the explanation of treatments also had a logical relationship with
the perception of necessity and concern, as it explained necessity
and lowered concerns. Educational level is negatively associated
with both necessity and concern to almost the same degree, which
should exclude the effect of this variable in a clinical situation.
Indeed it did not appear to have any direct effect on adherence.
Belief in powerful others showed an inconsistent association with
necessity and concern, as it increased both, but not to the same
extent. An explanation for this could be that a person who has great
impressions of their surroundings might get accurate information
regarding both risks and beneﬁts, which increases necessity and
concern.
4.2. Limitations
This study was of a cross-sectional type, which restricts the
possibility of causal conclusions. The data on adherence to
medication and NCF were self-reported, and therefore some of
the respondents may have underestimated or overestimated their
rate of adherence.
The research model was explorative, and in future studies the
model may be complemented by other factors of interest, e.g.
health beliefs [66,67], self-efﬁcacy [68–72] and socioeconomic
status [73], or tested in other theoretical approaches to investigate
factors of interest.
This was a sample with limited diversity based on self-
selection. No data on non-respondents were collected. To limit the
impact of possible selection bias the model was adjusted for
demographic variables such as age and gender. As such, utility and
effectiveness among diverse populations should be evaluated in
future research. In addition, this patient group was selected whilst
fetching their prescribed medications. Therefore, the results only
apply to secondary adherence behavior and should not be
generalized to patients that are not primary adherent, which
includes those patients who did not even purchase their
prescription drugs [74].
4.3. Conclusions
In conclusion, this study identiﬁed both the perception of
necessity of treatment and side effects as directly signiﬁcant
factors associated with adherence among patients using lipid-
lowering medical treatments. This study also provided preliminary
support for the notion that health- and treatment-related factors,
as well as locus of control factors, are indirectly associated with
medical adherence through their associations with mediating
perception of necessity of treatment.
Even though much of the adherence behavior is under the
patients’ control [64], this result shows that perception of the
necessity of treatment is associated with several modiﬁable
E. Berglund et al. / Patient Education and Counseling 91 (2013) 105–112 111factors, and that a high perception of the necessity of treatment is
associated with higher adherence among statin users. This
supports the idea that present health care professionals have
not seized the potential of increasing adherence in this patient
group to its full extent.
4.4. Practice implications
The study implies that it might be possible to increase
adherence by managing some of the modiﬁable factors that are
associated with CVD patients’ beliefs about medications. Impor-
tantly, patients’ satisfaction with treatment explanation seems to
have a positive association with treatment necessity and at the
same time a negative association with treatment concerns.
The study highlights the importance for health care profes-
sionals of considering beliefs about medications, disease burden,
experience of cardiovascular events and locus of control factors
that characterize the patient when it comes to increasing
adherence. The results of this study imply that an approach
targeting necessity and concern might be able to increase
adherence to statin therapy.
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